203 related articles for article (PubMed ID: 35794829)
1. Mechanisms of isoform-specific residue influence on GTP-bound HRas, KRas, and NRas.
Volmar AY; Guterres H; Zhou H; Reid D; Pavlopoulos S; Makowski L; Mattos C
Biophys J; 2022 Oct; 121(19):3616-3629. PubMed ID: 35794829
[TBL] [Abstract][Full Text] [Related]
2. Allosteric site variants affect GTP hydrolysis on Ras.
Johnson CW; Fetics SK; Davis KP; Rodrigues JA; Mattos C
Protein Sci; 2023 Oct; 32(10):e4767. PubMed ID: 37615343
[TBL] [Abstract][Full Text] [Related]
3. Wentilactone A as a novel potential antitumor agent induces apoptosis and G2/M arrest of human lung carcinoma cells, and is mediated by HRas-GTP accumulation to excessively activate the Ras/Raf/ERK/p53-p21 pathway.
Lv C; Hong Y; Miao L; Li C; Xu G; Wei S; Wang B; Huang C; Jiao B
Cell Death Dis; 2013 Dec; 4(12):e952. PubMed ID: 24309939
[TBL] [Abstract][Full Text] [Related]
4. Delineating the RAS Conformational Landscape.
Parker MI; Meyer JE; Golemis EA; Dunbrack RL
Cancer Res; 2022 Jul; 82(13):2485-2498. PubMed ID: 35536216
[TBL] [Abstract][Full Text] [Related]
5. KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation.
Lu J; Bera AK; Gondi S; Westover KD
Biochemistry; 2018 Jan; 57(3):324-333. PubMed ID: 29235861
[TBL] [Abstract][Full Text] [Related]
6. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
Johnson CW; Lin YJ; Reid D; Parker J; Pavlopoulos S; Dischinger P; Graveel C; Aguirre AJ; Steensma M; Haigis KM; Mattos C
Cell Rep; 2019 Aug; 28(6):1538-1550.e7. PubMed ID: 31390567
[TBL] [Abstract][Full Text] [Related]
7. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Hood FE; Sahraoui YM; Jenkins RE; Prior IA
Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
[TBL] [Abstract][Full Text] [Related]
8. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.
Quinlan MP; Quatela SE; Philips MR; Settleman J
Mol Cell Biol; 2008 Apr; 28(8):2659-74. PubMed ID: 18268007
[TBL] [Abstract][Full Text] [Related]
9. The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects.
Johnson CW; Reid D; Parker JA; Salter S; Knihtila R; Kuzmic P; Mattos C
J Biol Chem; 2017 Aug; 292(31):12981-12993. PubMed ID: 28630043
[TBL] [Abstract][Full Text] [Related]
10. Differential dynamics of RAS isoforms in GDP- and GTP-bound states.
Kapoor A; Travesset A
Proteins; 2015 Jun; 83(6):1091-106. PubMed ID: 25846136
[TBL] [Abstract][Full Text] [Related]
11. SmgGDS displays differential binding and exchange activity towards different Ras isoforms.
Vikis HG; Stewart S; Guan KL
Oncogene; 2002 Apr; 21(15):2425-32. PubMed ID: 11948427
[TBL] [Abstract][Full Text] [Related]
12. Improved binding of raf to Ras.GDP is correlated with biological activity.
Kiel C; Filchtinski D; Spoerner M; Schreiber G; Kalbitzer HR; Herrmann C
J Biol Chem; 2009 Nov; 284(46):31893-902. PubMed ID: 19776012
[TBL] [Abstract][Full Text] [Related]
13. Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele.
Zhang Y; Larraufie MH; Musavi L; Akkiraju H; Brown LM; Stockwell BR
Biochemistry; 2018 Feb; 57(8):1380-1389. PubMed ID: 29313669
[TBL] [Abstract][Full Text] [Related]
14. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors.
Sasaki AT; Carracedo A; Locasale JW; Anastasiou D; Takeuchi K; Kahoud ER; Haviv S; Asara JM; Pandolfi PP; Cantley LC
Sci Signal; 2011 Mar; 4(163):ra13. PubMed ID: 21386094
[TBL] [Abstract][Full Text] [Related]
16. Origin and Evolution of RAS Membrane Targeting.
García-España A; Philips MR
Oncogene; 2023 May; 42(21):1741-1750. PubMed ID: 37031342
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding.
Ting PY; Johnson CW; Fang C; Cao X; Graeber TG; Mattos C; Colicelli J
FASEB J; 2015 Sep; 29(9):3750-61. PubMed ID: 25999467
[TBL] [Abstract][Full Text] [Related]
18. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
19. Differential functions of the KRAS splice variants.
Kochen Rossi J; Nuevo-Tapioles C; Philips MR
Biochem Soc Trans; 2023 Jun; 51(3):1191-1199. PubMed ID: 37222266
[TBL] [Abstract][Full Text] [Related]
20. Conformational resolution of nucleotide cycling and effector interactions for multiple small GTPases determined in parallel.
Killoran RC; Smith MJ
J Biol Chem; 2019 Jun; 294(25):9937-9948. PubMed ID: 31088913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
